- Conditions
- Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
- Interventions
- Budesonide 3Mg Capsule, Standard of Care Prednisone
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 189
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Graft Versus Host Disease, Intestinal Graft Versus Host Disease
- Interventions
- Budesonide, Methylprednisolone Sodium Succinate
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- IgA Nephropathy
- Interventions
- TARPEYO®
- Drug
- Lead sponsor
- Calliditas Therapeutics AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Fresno, California + 30 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 92
- States / cities
- Jasper, Alabama • Mobile, Alabama • Tucson, Arizona + 89 more
- Conditions
- Asthma
- Interventions
- BDA MDI, AS MDI
- Drug
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 2,516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 61
- States / cities
- Mobile, Alabama • Paradise Valley, Arizona • Tempe, Arizona + 50 more
- Conditions
- Asthma
- Interventions
- Budesonide/formoterol pMDI, Budesonide HFA pMDI
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 46
- States / cities
- Muscle Shoals, Alabama • Little Rock, Arkansas • Anaheim, California + 43 more
- Conditions
- Cholangitis, Sclerosing, Liver Cirrhosis, Biliary
- Interventions
- budesonide
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1999
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Crohn's Disease
- Interventions
- EBFAHF-2, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Malignant Melanoma
- Interventions
- Ipilimumab+ Placebo, Ipilimumab+ Budesonide
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • Charlotte, North Carolina + 1 more
- Conditions
- Asthma
- Interventions
- pMDI budesonide/formotrol 160/4.5 is in group 1, Symbicort 160/4.5 plus Aerochamber Plus included in group 2
- Drug · Device
- Lead sponsor
- Western Sky Medical Research
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- Asthma, Lung Diseases
- Interventions
- Inhaled Corticosteroid (Budesonide), Leukotriene Receptor Antagonist (Montelukast Sodium), Inhaled Albuterol
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 12 Months to 59 Months
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • La Jolla, California • Denver, Colorado + 3 more
- Conditions
- Ulcerative Colitis
- Interventions
- Budesonide MMX 6 mg Tablet, Placebo Tablet
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 53
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 46 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Budesonide / Formoterol, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- COPD
- Interventions
- BGF MDI 320/14.4/9.6 μg, GFF MDI (PT003) 14.4/9.6 μg, BFF MDI (PT009) 320/9.6 μg, Symbicort® Turbuhaler® (TBH) Inhalation Powder
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 1,902 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 63
- States / cities
- Andalusia, Alabama • Jasper, Alabama • Peoria, Arizona + 54 more
- Conditions
- Asthma
- Interventions
- BDA MDI, AS MDI
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 117
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 93 more
- Conditions
- Proctitis, Proctosigmoiditis
- Interventions
- Budesonide Foam
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Asthma, Nonadherence, Medication
- Interventions
- Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- budesonide, placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Orange, California • Palo Alto, California + 15 more
- Conditions
- Asthma
- Interventions
- BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 2,187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 88
- States / cities
- Chandler, Arizona • Tempe, Arizona • Tucson, Arizona + 78 more
- Conditions
- Early Stage HER2+ Breast Cancer
- Interventions
- Neratinib, Loperamide, Colestipol, Budesonide
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Corona, California • Fullerton, California + 36 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Oral Budesonide, Elimination diet
- Drug · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Asthma, Asthma Attack, Asthma Exacerbations
- Interventions
- Inhaled corticosteroid (ICS), Azithromycin, Asthma Symptom Monitoring Web-based Application
- Drug · Other
- Lead sponsor
- DARTNet Institute
- Government
- Eligibility
- 13 Years to 75 Years
- Enrollment
- 3,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Orlando, Florida • Kansas City, Kansas + 9 more
- Conditions
- Asthma
- Interventions
- Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Albuterol sulfate metered-dose inhaler 180 μg
- Combination Product · Drug
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 3,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 170
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 139 more
- Conditions
- Mild Asthma
- Interventions
- Albuterol/Budesonide, Albuterol
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Lancaster, California + 13 more